GenFleet Therapeutics (Shanghai) Inc. (Stock Code: 2595) announced that it will be added to multiple Hang Seng Index Series and the MSCI Global Small Cap Index. According to the quarter-end review by Hang Seng Indexes Company Limited on February 13, 2026, GenFleet is set to join the Hang Seng Composite Index (HSCI), Hang Seng Stock Connect Hong Kong Index, and Hang Seng Innovative Drug Index, among others, effective March 9, 2026. The inclusion in the MSCI Global Small Cap Index takes effect after the close of trading on February 27, 2026.

GenFleet’s shares will also be included in additional Hang Seng sub-indices, such as the Hang Seng Composite MidCap & SmallCap Index, Hang Seng Composite SmallCap Index, Hang Seng SCHK Mainland China Companies Index, and other related healthcare and innovative drug indices. The Hang Seng Composite Index covers the top 95% of listed companies by cumulative market capitalization on the HKEX Main Board.

The board of directors states that entering multiple benchmark indices underscores recognition of the company’s ongoing value and growth potential, potentially increasing share liquidity and diversifying its investor base. GenFleet focuses on RAS-targeted therapeutics as part of its pipeline in oncology and autoimmune diseases. It leverages an integrated research and development platform—from target discovery to manufacturing—to advance treatments for unmet medical needs. The company’s approach includes novel molecular modalities and explorations of clinical development routes to capture significant market opportunities in China and globally.